#United States #New York #pharmaceutical #Havas Health #BrightInsight

Havas Health and BrightInsight: A New Era in Patient Adherence

In a groundbreaking move to enhance patient treatment experiences, Havas Health has established a strategic partnership with BrightInsight, a leader in digital health platforms for biopharma. This alliance promises to revolutionize the way healthcare providers approach patient adherence and persistence, addressing significant challenges that cost the pharmaceutical industry an estimated $500 billion annually due to poor patient adherence.

A Unique Collaboration

This partnership marks a unique collaboration whereby Havas Health will become BrightInsight’s sole global agency partner, integrating their renowned healthcare strategy with BrightInsight’s state-of-the-art digital health platform. The objective is to support patients after they receive their prescriptions, ensuring that therapy effectiveness translates from a clinical to a real-world scenario.

According to Jeff Hoffman, Chief Development Officer of Havas Health Network, the industry is shifting. Clients are not merely questioning if they should adopt digital solutions but are looking for efficient, proven methods to do so across various markets. By introducing BrightInsight's platform into their service offerings, Havas Health is digging deeper into digital communication, offering a pre-vetted, regulatory-ready solution that guarantees an outstanding patient experience aligned with their treatment regimen.

Addressing Critical Friction Points

The collaboration specifically targets a crucial friction point in pharmaceuticals: the gap between the prescribing of groundbreaking therapies and achieving their real-world effectiveness. As treatment protocols become increasingly complicated, many patients are managing chronic illnesses that necessitate lifelong care. INSIGHTS from recent industry reports emphasize that adherence and persistence are the two major hindrances to clinical success. BrightInsight’s technology, which has already shown to improve therapy continuation and adherence by significant margins compared to traditional support programs, stands out as a solution.

BrightInsight's compliant technologies enable healthcare brands to maintain a standardized support system while customizing the patient experience. This dual benefit has the potential to drastically reduce therapy dropout rates and enhance patient satisfaction. With applications in over 60 countries, these methodologies have been proven effective with leading biopharma companies, fostering consistent clinical and commercial impacts.

The Future of Healthcare

Havas Health's commitment to innovation is further evidenced by previous collaborations with platforms like Ostro and Vurvey, showcasing ongoing investments aimed at enhancing client trust and value. Both companies agree that success in this digital health initiative hinges on their ability to integrate seamlessly into patients' daily lives, driving tangible benefits while improving health outcomes across the board.

Kal Patel, MD, CEO, and Co-Founder of BrightInsight, remarked on the potential of this partnership to fuse digital innovation with substantial commercial scalability. By leveraging Havas's strategic know-how alongside BrightInsight's technological prowess, they can embed digital health solutions at the core of biopharma brands, thereby ensuring they are as impactful for patients as the therapies themselves.

These forward-thinking approaches and innovative strategies reflect a collective commitment from both firms to push the boundaries of healthcare communication and technology. As both Havas Health and BrightInsight embark on this journey together, the future of patient engagement, adherence, and overall health management looks promising.

For more information about Havas Health, visit Havas Health Network. More on BrightInsight can be found on their website.